

NOD SCID

系統名 NOD.Cg-*Prkdc*^{scid}/NifdcSmoc

SMOC番号 SM-019

維持形態 Repository Live

遺伝子の概要

Gene Symbol Prkdc	Synonyms	p460, DNA- PKcs, scid, XRCC7, slip, DNAPK, DNPK1, HYRC1, dxnph, DOXNPH, DNAP Dcs, AU019811, Al326420
	NCBI ID	<u>19090</u>
	MGIID	104779
	Ensembl ID	ENSMUSG00000022672

説明

The scid mutation has been transferred onto a diabetes-susceptible Non-Obese Diabetic (NOD) background. NOD-Scid mice do not develop diabetes, lack T and B cells, and are inherently immune deficient, making them good recipients for transplantation of human hematopoietic stem cells and human solid tumors.

*Literature published using this strain should indicate: NOD SCID mice (Cat. NO. SM-019) were purchased from Shanghai Model Organisms Center, Inc..

表現型デロタ



NOD SCID body Weight Growth Curve




Fig1. Body weight growth curve of NOD SCID (n=168)




Fig 2. Detection of serum antibody subclasses in NOD SCID mice (8-week old, male).






Fig3. Complete deletion of T, B and NK cells of NOD SCID mice. Spleen and peripheral blood cells NOD SCID mice were collected to analyze their compositions of T, B and NK cells by FACS.




Fig4. Complete deletion of Monocytes, macrophages and DC cells of NOD SCID mice. Spleen and peripheral blood cells NOD SCID mice were collected to analyze their compositions of Monocytes, macrophages and DC cells by FACS.






Fig5. Pathological examination of various tissues in NOD SCID mice. Thymus was absent in NOD SCID mice, and no significant pathologic abnormalities were found in the other tissues examined (8-week old, A males, B females).




Fig6. Subcutaneous xenograft tumor growth in NOD SCID.



Parameter		NOD SCID; Male	NOD SCID; Female
	Units	8-10 weeks; n=10	8-10 weeks; n=10
WBC	103 cells/µL	2.21±0.22	1.86±0.25
RBC	106 cells/µL	9.14±0.10	9.40±0.13
HGB	g/dL	14.33±0.19	15.13±0.18
HCT	%	48.85±0.61	50.19±0.52
MCV	fL	53.45±0.15	53.42±0.35
MCH	pg	15.67±0.09	16.10±0.06
MCHC	g/dL	29.34±0.14	30.15±0.19
PLT	10 ⁶ cells/µL	2330.70±75.89	1788.10±58.85
RDW-SD	fL	33.90±0.28	34.39±0.16
RDW-CV	96	20.29±0.16	20.77±0.20
PDW	fL	8.03±0.13	8.36±0.26
MPV	fL	7.17±0.09	7.36±0.14
P-LCR	%	7.54±0.43	8.63±0.89
PCT	96	1.67±0.05	1.31±0.03
NEUT#	103 cells/μL	0.14±0.05	0.26±0.10
LYMPH#	103 cells/μL	1.65±0.17	1.27±0.22
MONO#	103 cells/μL	0.42±0.07	0.24±0.04
EO#	103 cells/μL	0.05±0.01	0.06±0.02
BASO#	103 cells/μL	0.01±0.00	0.02±0.01
NEUT%	96	5.64±1.86	14.19±5.07
LYMPH%	%	73.58±1.65	67.65±5.96
MONO%	96	18.03±1.72	13.04±1.25
EO%(%)	%	2.13±0.34	3.85±1.58
BASO%	%	0.57±0.16	1.27±0.51
RET#	10 ⁶ cells/μL	0.51±0.01	0.62±0.02
RET%	%	5.53±0.12	6.59±0.22
LFR(%)	%	44.74±0.71	45.77±0.63
MFR(%)	%	19.11±0.54	18.81±0.39
HFR(%)	%	36.15±0.50	35.42±0.44
IRF(%)	%	55.26±0.71	54.23±0.63

Fig7. Blood routine tests in NOD SCID.



Parameter		NOD SCID; Male	NOD SCID; Female
	Units	8-10 weeks; n=10	8-10 weeks; n=10
TP	g/L	57.50±0.83	56.50±0.76
ALB	g/L	26.00±0.67	26.00±0.67
ALP	U/L	255.00±14.62	458.00±11.65
ALT	U/L	155.00±55.99	131.50±79.08
AST	U/L	258.00±49.65	310.00±122.93
T-BIL	µmol/L	2.81±0.17	1.68±0.20
D-BIL	µmol/L	2.58±0.12	2.43±0.39
CHE	U/L	4459.00±121.79	8907.00±233.85
CRE	µmol/L	18.60±0.32	19.67±0.72
BUN	mmol/L	11.00±0.21	10.25±0.35
UA	µmol/L	210.35±20.89	229.00±20.54
тсно	mmol/L	2.97±0.08	2.19±0.07
TG	mmol/L	1.07±0.09	0.73±0.09
HDL	mmol/L	2.98±0.09	2.19±0.07
LDL	mmol/L	1.92±0.03	2.00±0.02
NEFA	mmol/L	1.11±0.04	0.87±0.05
LDH	U/L	976.00±126.31	1021.00±201.50
СК	U/L	638.50±137.07	843.50±202.90
Hoy	µmol/L	5.05±0.05	6.69±0.68
GLU	mmol/L	12.12±0.97	11.58±0.68
Ca	mmol/L	3.25±0.07	3.33±0.07
IP	mmol/L	3.30±0.11	4.10±0.38
Fe	µmol/L	62.15±2.57	57.55±2.62
CRP	mg/L	0.00±0.00	0.00±0.00

Fig8. Blood biochemistry in NOD SCID.

Table 1. NOD SCID xenograft cell lines

Cancer Type	Cell Lines (100+)	
Breast	MCF-7/5C, MCF-7/TAM2, MCF-7/RAL2, MCF-7/RAL1, MCF-7/E2, MCF-7, MDA-MB-231, T47D, BT-20, MDA-MB-435, MCF10A, MDA-MB-435/LCC6, MCF-7LU, M4A4-LM, SUM149PT	
Lung	HCC827, NCI-H358, A549, NCI-H1299, LT391-06, SK-MES-1, Calu-3, NCI-H460, NCI-H2126, NCI-H1975, NYH, NCI-H727, GLC19	
Liver	Hep3B2.1-7, HepG2	
Prostate	LNCaP, VCaP, PC-3, LNCaPC4-2B, LAPC-4, DU145, PC-82, PC-310, PC-295, PC346-DCC-K, PC3-MM2, PC-346C	
Melanoma	SK-MEL-31, SK-MEL-28, SK-MEL-5, A-375, WM1617, WM9, G-361	
Colon	T84, HT-29, HCT116, LS174T, SW620	
Bladder	KU-19-19, URO-MSC24, URO-ASC, UROtsa, URO-MSC52, RT4	
Ovarian	TOV-21G, TOV-112D, A2780, OVCAR-3, A2780/CP70, A2780cis	
Pancreatic	BxPC-3, Capan-1, MIAPaCa-2, PANC-1, L3.6pl, HPAF-II	
Glioma	BT-40, A-172	
Kidney	786-O	
Carcinoma	A-498	
Cervical	HeLa	
Myeloma	INA-6	
Stomach	MKN28, NCI-N87, MKN45	
Adenocarcinoma	KB-C2, KB-3-1	
Others	U-251MG, Caki-1, AN3CA, HT-1080	

